Size | Price | Stock | Qty |
---|---|---|---|
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
In ZAZ and M14 melanoma cell lines, 48 hours of treatment with L-buthionine-(S,R)-suLfoximine (BSO: 50 μM) led to a 95% reduction in GSH levels and a 60% reduction in GST enzyme activity. The cellular oxidative intermediate g-glutamine is induced in different cell lines by GST-π L-butyrine-(S,R)-suLfoximine (BSO) through irreversibly blocking g-glutamine cysteine synthetase Amide protein and mRNA levels were drastically reduced [1]. An enzyme called semiphosphatidylamine synthetase is necessary for the production of glutathione (GSH) [2]. Ferroptosis is induced by L-butanthionine-(S,R)-suLfoximine (BSO) [3].
|
---|---|
ln Vivo |
In developing mice, BSO raises the frequency of DNA. In comparison to animals that were not treated, BSO therapy decreased GSH levels in mice that were given 2 mM and 20 mM BSO, respectively, by 55% and 70%. GSH was outpaced by co-treatment with 2 mM BSO and 20 mM NAC. The degree is comparable to that of 2 mM BSO, which is in line with BSO's ability to inhibit the g-GCS enzyme, which is responsible for the synthesis of dyes from GSH. C57BL/6J pun/pun mice are an animal model for cysteine modules, similar to GSH, following BSO therapy [2].
|
Animal Protocol |
Animal/Disease Models: C57BL/6J pun/pun mice[2].
Doses: 2 mM L-Buthionine-(S,R)-sulfoximine (BSO), 20 mM BSO, 2 mM BSO and 20 mM NAC, 20 mM NAC or unsupplemented water for 18 days from 0.5 to 18.5 d.p.c. The pH of supplemented water is as follows: 6.88, 20 mM BSO; 3.37, 2 mM BSO; 2.65, 2 mM BSO plus 20 mM NAC; and 2.58, 20 mM NAC. The pH of regular water used in our facility is ~4. Route of Administration: Drinking water Experimental Results: The average number of eye-spots (mean±SEM) is 5.36±0.29 (n=46), 7.79±0.45 (n=34) and 8.78±0.61 (n=32) in untreated controls, 2 mM L-Buthionine-(S,R)-sulfoximine (BSO) and 20 mM BSO treated mice, respectively. The 2 mM BSO treatment results in ~30% more eye-spots, and the 20 mM treatment results in 40% more eye-spots compared with untreated mice. |
References |
[1]. Fruehauf JP, et al. Selective and synergistic activity of L-S,R-buthionine sulfoximine on malignant melanoma is accompanied by decreased expression of glutathione-S-transferase. Pigment Cell Res. 1997 Aug;10(4):236-49.
[2]. Reliene R, et al. Glutathione depletion by buthionine sulfoximine induces DNA deletions in mice. Carcinogenesis. 2006 Feb;27(2):240-4. [3]. Satoru Nishizawa, et al. Low tumor glutathione level as a sensitivity marker for glutamate-cysteine ligase inhibitors. Oncol Lett. 2018 Jun;15(6):8735-8743. |
Molecular Formula |
C8H18N2O3S
|
---|---|
Molecular Weight |
222.3051
|
CAS # |
83730-53-4
|
Related CAS # |
DL-Buthionine-(S,R)-sulfoximine;5072-26-4;L-Buthionine-(S,R)-sulfoximine hydrochloride
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
S(C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])(C([H])([H])C([H])([H])[C@@]([H])(C(=O)O[H])N([H])[H])(=N[H])=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~18.33 mg/mL (~82.45 mM)
DMSO :< 1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (449.82 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.4982 mL | 22.4911 mL | 44.9822 mL | |
5 mM | 0.8996 mL | 4.4982 mL | 8.9964 mL | |
10 mM | 0.4498 mL | 2.2491 mL | 4.4982 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.